News Updates
Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema
Read moreIntellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
Read moreOur
Mission
To transform the lives of people with severe diseases by developing and commercializing potentially curative treatments.
Learn more

